The COVID-19 research database enables public health and policy researchers to use real-world data to better understand and combat the COVID-19 pandemic. The database is a pro-bono, cross-industry collaborative, composed of institutions donating technology services, healthcare expertise, and de-identified data. The database is a public-private consortium organized by Datavant, Health Care Cost Institute, Medidata, Mirador Analytics, Veradigm, Change Healthcare, Snowflake and many others. Please refer to our the partners below for the full list.
The database includes de-identified and limited datasets from medical and pharmacy claims data, EHR data, mortality data, and consumer data.
COVID-19 Research Database Publications
Research is key to mitigating the impacts of COVID-19 across the healthcare system and society. Here is a sampling of the many publications so far about the database:
The group consists of a representative from all contributing data sources and institutions. This group designed the governance structure for the database, ensuring that data is used in ways consistent with its intent and ensuring the highest level of security and patient protection.
Founder & CEO, Healthjump
Chief Executive Officer & Founder, Mirador Analytics
President & Chief Executive Officer, Health Care Cost Institute
MHA, MPA, Senior Vice President, Product - Acorn AI, a Medidata company.
Head of Healthcare & Life Sciences, Snowflake
MD, President of Clinical Solutions, Elsevier
President, CPO, and Co-Founder, Clarify Health Solutions
Vice President, Corporate Development & Strategic Partnerships, Symphony Health
PharmD, Medical Director, SAS
PhD, Chief Strategy Officer, Datavant
CEO, Office Ally
MBA, Vice President & General Manager of Life Sciences, Veradigm
Patrick J. Sullivan
Senior Vice President, Integrated Analytics, North America Life
Senior Vice President, Data Solutions, Change Healthcare
Executive Director of Marketing, Stata
The group consists of industry leaders and This group identifies ways to enhance the database’s impact on COVID-19 research, including identifying opportunities to collaborate with other initiatives.
Donald M. Berwick
David J. Shulkin
MD, Former Secretary of the US Department of Veterans Affairs, MD
Chief Strategy Officer at LifeOmic, Former HHS CTO
M.B., B.Ch., M.P.H., FAAP, President and CEO, AcademyHealth
PhD, President of Science Advisors, LLC
CEO, Evergreen Strategic Advisors, MBA
The group consists of expert statisticians, ensuring that all data in the database and proposed combinations of data sets are de-identified.
PhD, Scheuren Ruffner Consultants
PhD, MPH, Assistant Professor of Clinical Epidemiology, Columbia
PHD, Founder, Singular Value Consulting
J.D., Senior Vice President, Deputy General Counsel & Chief Privacy Counsel, Medidata
PhD, Professor of Biomedical Informatics, Biostatistics, and Computer Science, Vanderbilt University
PhD, MSc, MRes, Chief Data Scientist, Mirador Analytics
The group ensures that the voice of the patient and the patient experience is captured in proposals and that the database meets high ethical standards.
Donna R. Cryer
J.D., President & CEO of the Global Liver Institute
J.D., MPH, Chief Regulatory Officer, Ciitizen
Principal at Participatory Health Consulting
Andrew C. Wicks
Ruffin Professor of Business Administration, Director, Olsson Center for Applied Ethics
The group reviews all submitted proposals for research to be conducted in the database, ensuring that studies are scientifically rigorous and of the standard to be accepted by peer reviewed publications.
Mark Cullen, Committee Chair
MD, Professor of Medicine at Stanford University Schoool of Medicine.
PhD, Director of the Center for Clinical Informatics & Improvement Research, UCSF
PhD, MS, LPHI and REACHnet
C. Lee Cohen
MD MBA, a Pulmonary and Critical Care Fellow at Brigham and Women's Hospitals
MPH, Global Lead, Epidemiology and RWE & Global Lead, COVID-19 Epi-response Team, SAS
MD, RWE Head of Research, Acorn.ai
VP, Policy, Devoted Health
MD, Executive Director, Massachusetts General Hospital Center for Global Health
PhD, MPH, Senior Clinical Consultant, Veradigm
PharmD, MBA, FCCP, DAAPM, President Medical Outcomes Management and Co-founder PRACnet
MD, MS, FACMI, Director of the Institute for Augmented Intelligence in Medicine
Gregory P. Licholai
MD, Chief Medical Information Officer, PRA
PhD, Founder & CEO, BHE
PhD, Professor of Economics, Harvard University
MD, Professor of Medicine and of Health Research & Policy at Stanford
PhD, Rubenstein Fellow, Duke University
Global AI Healthcare Principal & COVID-19 Global Scientific Advisory Team, SAS
MD, Professor of Epidemiology & Biostatistics, Harvard T.H. Chan School of Public Health
MD, MS, FACMI, Professor of Medicine at Harvard Medical School
MBA, Managing Director, Berkeley Research Group
PhD, Corporate VP, Biostatistics and Statistical Programming at Parexel
PhD, Assistant Professor at the University of Chicago Department of Economics
PhD, MSPH, Director, Center for Predictive Medicine, Duke Clinical Research Institute
The group investigates ways to incorporate omics data and research into the database.
Chief Math Officer, GNS Healthcare
Chief Technology Officer and VP Strategy & Insights, Qiagen
VP, Data Science, Qiagen
Chief Commercial Officer, Glooko
Chief Growth Officer, Aetion
Corporate Vice President, Global Data Operations, Parexel
Strategic Advisory Board, Genstar Capital
How it Works
- Researchers are welcome to register to request access to the COVID-19 Research Database Knowledge Base and the ability to submit research proposals.
- Register with your organizational affiliation. Personal emails will not be accepted.
- Access can be granted only if you intend to conduct non-commercial, non-financial, non-legal-related research.
- Registration requires approval before access is granted. A decision is typically made within 1 business day.
- Once registration is complete, you'll have access to the full knowledge base to learn about the full submission process, the types of datasets accessable, the analytics tools availble and more.
Research Database Principles
- Commercially-sponsored research: Any study paid for, sponsored by, or conducted to serve a sponsor for a commercial application (e.g. feasibility study for a sponsored clinical trial, a health economics and outcome research study to gain favorable reimbursement with payers, outcomes study to show your facility is superior to others in the area, etc.).
- Legal research: Any study to support a legal proceeding (e.g. lawsuit, criminal defense or prosecution, etc.).
- Financial research: Any study to support investing, trading, mergers, acquisitions, divestments, or similar professional or personal finance activities.